



Supplementary data 1. Overview of samples used for the assessment of prevalence, type specific concordance and clinical performance of the Xpert HPV.

Of the VALGENT 2 set (upper image) 1296 samples were technically valid. HR-HPV prevalence (as detailed in figure 1) was assessed using “a” and type specific concordance for HPV 16 and 18/45 was assessed using a & b. A total of 943 had follow up/outcome data and (c & d) were used for the assessment of clinical performance of the Xpert HPV in absolute terms and also in relation to a clinically validated reference test. Clinical performance of the Xpert was also assessed by aggregating data from VALGENT 2 with that of Cuzick et al¹ (lower image) where a total of 3408 women had follow up/outcome data related to the Xpert HPV and a clinically validated reference test, permitting assessment of 4351 outcomes (c-f). Note the samples used for inter and intra-laboratory agreement were outside of the above sample pool with this element of the analysis performed between Ghent and Antwerp in Belgium.

References

- 1- Cuzick J, Cuschieri K, Denton K, Hopkins M, Thorat MA, Wright C, Cubie H, Moore C, Kleeman M, Austin J, Ashdown-Barr L, Hunt K, Cadman L. 2015. Performance of the Xpert HPV assay in women attending for cervical screening. *Papillomavirus Research* 1: 32-37